Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Nov 29;12(11):162.
doi: 10.1038/s41408-022-00758-7.

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial

Karthik Ramasamy #  1   2   3 , Gulnaz Iqbal #  4 , Richard Brouwer  5   6 , Victoria Stalker  5 , Salma Akhtar  5 , Sherin Varghese  5   6 , Jindriska Lindsay  7 , Stephen Schey  8 , Mark Drayson  9 , Janet Dunn  4
Affiliations
Clinical Trial

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial

Karthik Ramasamy et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

All authors completed the ICMJE disclosure form. The following personal or financial relationships relevant to this manuscript existed during the conduct of the study. KR reports honoraria, research grant from Janssen, Celgene, Takeda, and Amgen. He also reports advisory boards from Celgene, Takeda, Janssen, Amgen, Abbvie, Sanofi, Oncopeptides, Karyopharm, GSK, Adaptive biotech, Pfizer, and speaker’s bureau from Celgene, Takeda and Adaptive Biotech. MD owns shares in Abingdon Health.

References

    1. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53:207–12. doi: 10.1111/j.1600-0609.1994.tb00190.x. - DOI - PubMed
    1. Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–93. doi: 10.1001/archinte.158.17.1889. - DOI - PubMed
    1. Torra R, Bladé J, Cases A, López-Pedret J, Montserrat E, Rozman C, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol. 1995;91:854–9. doi: 10.1111/j.1365-2141.1995.tb05400.x. - DOI - PubMed
    1. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002–Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219–26. doi: 10.1200/JCO.2005.03.2086. - DOI - PubMed
    1. Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91:499–502. doi: 10.1002/ajh.24335. - DOI - PubMed

MeSH terms